| Systemic Sclerosis and Related Diseases | Lifetime | 325 | CN 5 | 97.47 |
| Systemic Lupus Erythematosus Research | Lifetime | 756 | CN 22 | 97.82 |
| Vasculitis and related conditions | Lifetime | 252 | CN 6 | 97.41 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 668 | CN 12 | 97.00 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 276 | CN 3 | 96.10 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 972 | CN 19 | 96.51 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 278 | CN 16 | 92.15 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 604 | CN 12 | 85.66 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 53 | CN 5 | 98.83 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 84 | CN 1 | 98.40 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 70 | CN 1 | 97.02 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 53 | CN 6 | 96.46 |
| Vasculitis and related conditions | 2021-2025 | 53 | CN 2 | 97.90 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 260 | CN 25 | 95.49 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 177 | CN 4 | 95.69 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 108 | CN 8 | 94.52 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 659 | CN 31 | 93.63 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 350 | CN 36 | 93.17 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 234 | CN 10 | 90.38 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 497 | CN 76 | 91.57 |
| Platelet Disorders and Treatments | 2021-2025 | 332 | CN 30 | 90.54 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 374 | CN 21 | 89.37 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 292 | CN 81 | 81.51 |
| Bone and Joint Diseases | 2021-2025 | 423 | CN 103 | 82.21 |
| Liver Diseases and Immunity | 2021-2025 | 514 | CN 41 | 84.58 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 898 | CN 28 | 83.10 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 801 | CN 98 | 83.88 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 141 | CN 31 | 79.36 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 783 | CN 103 | 78.86 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 858 | CN 48 | 74.90 |
| Blood disorders and treatments | 2021-2025 | 579 | CN 24 | 68.60 |
| Salivary Gland Disorders and Functions | 2021-2025 | 890 | CN 179 | 69.48 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 993 | CN 221 | 66.70 |
| Vascular Anomalies and Treatments | 2021-2025 | 424 | CN 33 | 63.79 |
| Connective Tissue Growth Factor Research | 2021-2025 | 183 | CN 38 | 47.13 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 447 | CN 151 | 45.02 |
| Protein Tyrosine Phosphatases | 2021-2025 | 840 | CN 179 | 39.19 |
| Aortic Thrombus and Embolism | 2021-2025 | 221 | CN 10 | 30.84 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 762 | CN 232 | 34.36 |
